A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice

The use of C3d, the final degradation product of complement protein C3, as a “natural” adjuvant has been widely examined since the initial documentation of its immunogenicity-enhancing properties as a consequence of binding to complement receptor 2. Subsequently it was demonstrated that these effect...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yong-Gang, Pappworth, Isabel Y., Rossbach, Andreas, Paulin, Joshua, Mavimba, Tarirai, Hayes, Christine, Kulik, Liudmila, Holers, V.Michael, Knight, Andrew M., Marchbank, Kevin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849677/
https://www.ncbi.nlm.nih.gov/pubmed/29017821
http://dx.doi.org/10.1016/j.imbio.2017.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849677/
https://www.ncbi.nlm.nih.gov/pubmed/29017821
http://dx.doi.org/10.1016/j.imbio.2017.10.002

Ejemplares similares